The Accuracy of MicroRNA-210 in Diagnosing Lung Cancer: a Systematic Review and Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Aug 25

PMID 27557519

Citations 3

Authors

Huqin Yang

Huijuan Wang

Chao Zhang

Zhaohui Tong

Affiliations

Soon will be listed here.

Abstract

Studies examining the diagnostic value of microRNA-210 for lung cancer have yielded inconsistent results. Here, we performed a meta-analysis to assess the diagnostic accuracy of microRNA-210 for lung cancer. Nine eligible studies involving 993 patients (554 lung cancer patients and 439 non-cancer patients) were independently identified, and the quality of these studies was assessed according to Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) guidelines. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.66 (95% CI, 0.57 to 0.75), 0.82 (95% CI, 0.72 to 0.89), 3.64 (95% CI, 2.54 to 5.21), 0.41 (95% CI, 0.34 to 0.51) and 8.78 (95% CI, 6.10 to 12.66), respectively. The area under the summary receiver operator characteristic curve was 0.80 (95% CI, 0.76 to 0.83). These results indicated that microRNA-210 had moderate diagnostic value for lung cancer. Additional prospective studies are needed to confirm the diagnostic value of microRNA-210.

Citing Articles

Serum human epididymis Protein-4 outperforms conventional biomarkers in the early detection of non-small cell lung cancer.

Zare M, Nasir Kansestani A, Wu X, Zhou L, Lu J, Huang J iScience. 2024; 27(11):111211.

PMID: 39524348 PMC: 11550588. DOI: 10.1016/j.isci.2024.111211.

Simultaneous Detection of Tumor Derived Exosomal Protein-MicroRNA Pairs with an Exo-PROS Biosensor for Cancer Diagnosis.

Hsu C, Yang Y, Kannisto E, Zeng X, Yu G, Patnaik S ACS Nano. 2023; 17(9):8108-8122.

PMID: 37129374 PMC: 10266547. DOI: 10.1021/acsnano.2c10970.

Diagnostic significance of miR-210 as a potential tumor biomarker of human cancer detection: an updated pooled analysis of 30 articles.

Feng S, He A, Wang D, Kang B Onco Targets Ther. 2019; 12:479-493.

PMID: 30666127 PMC: 6331190. DOI: 10.2147/OTT.S184564.

References

Reddy K . MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015; 15:38. PMC: 4424445. DOI: 10.1186/s12935-015-0185-1. View

Li Z, Zhang H, Yang Z, Wen G, Cui Y, Shao G . Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer. J Int Med Res. 2013; 41(5):1437-44. DOI: 10.1177/0300060513497560. View

Chen L, Jin H . MicroRNAs as novel biomarkers in the diagnosis of non-small cell lung cancer: a meta-analysis based on 20 studies. Tumour Biol. 2014; 35(9):9119-29. DOI: 10.1007/s13277-014-2188-2. View

Shen J, Todd N, Zhang H, Yu L, Lingxiao X, Mei Y . Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2010; 91(4):579-87. PMC: 3130190. DOI: 10.1038/labinvest.2010.194. View

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

Bertoli G, Cava C, Castiglioni I . MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. Int J Mol Sci. 2016; 17(3):421. PMC: 4813272. DOI: 10.3390/ijms17030421. View

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

Ivan M, Huang X . miR-210: fine-tuning the hypoxic response. Adv Exp Med Biol. 2013; 772:205-27. PMC: 4515752. DOI: 10.1007/978-1-4614-5915-6_10. View

Hamza T, Arends L, van Houwelingen H, Stijnen T . Multivariate random effects meta-analysis of diagnostic tests with multiple thresholds. BMC Med Res Methodol. 2009; 9:73. PMC: 2787531. DOI: 10.1186/1471-2288-9-73. View

10.

Puissegur M, Mazure N, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K . miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2010; 18(3):465-78. PMC: 3131992. DOI: 10.1038/cdd.2010.119. View

11.

Deeks J, Macaskill P, Irwig L . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58(9):882-93. DOI: 10.1016/j.jclinepi.2005.01.016. View

12.

Tekcham D, Tiwari P . Non-coding RNAs as emerging molecular targets of gallbladder cancer. Gene. 2016; 588(1):79-85. DOI: 10.1016/j.gene.2016.04.047. View

13.

Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H . Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer. PLoS One. 2016; 11(4):e0153046. PMC: 4836744. DOI: 10.1371/journal.pone.0153046. View

14.

Inamura K, Ishikawa Y . MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment. J Clin Med. 2016; 5(3). PMC: 4810107. DOI: 10.3390/jcm5030036. View

15.

Mraz M, Malinova K, Mayer J, Pospisilova S . MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun. 2009; 390(1):1-4. DOI: 10.1016/j.bbrc.2009.09.061. View

16.

Zhao C, Lu F, Chen H, Zhao F, Zhu Z, Zhao X . Clinical significance of circulating miRNA detection in lung cancer. Med Oncol. 2016; 33(5):41. DOI: 10.1007/s12032-016-0757-5. View

17.

Fagan T . Letter: Nomogram for Bayes's theorem. N Engl J Med. 1975; 293(5):257. DOI: 10.1056/NEJM197507312930513. View

18.

Qin Q, Furong W, Baosheng L . Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer Res. 2014; 33:50. PMC: 4060094. DOI: 10.1186/1756-9966-33-50. View

19.

Shen J, Liu Z, Todd N, Zhang H, Liao J, Yu L . Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011; 11:374. PMC: 3175224. DOI: 10.1186/1471-2407-11-374. View

20.

Munagala R, Aqil F, Gupta R . Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumour Biol. 2016; 37(8):10703-14. DOI: 10.1007/s13277-016-4939-8. View